Annals of Oncology 1:175-181, 1990
© 1990 European Society for Medical Oncology
research-article |
Responses and toxic deaths in Phase I clinical trials*
1Department of Clinical Research, Division of Oncology, F. Hoffmann-LaRoche Ltd CH-4002 Basle, Switzerland
2Statistics for Research, SFR Ltd CH-4051 Basle, Switzerland
Correspondence to: Genevieve Decoster, M.D. Department of Clinical Research-Oncology F. Hoffmann-LaRoche Ltd Grenzacherstrasse 124 CH-4002 Basle, Switzerland
This review analysis consists of the antitumor activity and toxic deaths reported in single agent Phase I clinical trials using cytotoxic compounds published from 1972 to 1987. A total of 6639 patients with a variety of solid tumors and hematological malignancies were accrued in 211 trials studying 87 compounds. The median number of patients per trial was 28 (range: 7–111) and the median of the median ages reported in the individual trial was 56 (range of individual age: 2 to 93 years). Ten percent of the trials enrolled pediatric patients (< 18 years), but the exact numbers of children were not always given or separated from the adult patients. Nine percent of the patients had received no prior treatment, 75% were pretreated either with chemotherapy alone (50%) or radio- plus chemotherapy (25%). Radiotherapy alone was adminis-tered to 11% of the patients and the remaining 5% of the patients received prior treatments which was not specified. The most frequent tumor types were those of the gastrointestinal tract (22%) and the respiratory tract (19%). The frequency of the remaining malignancies was < 10% of all patients. There were 23 (0.3%) complete responders and 279 (4.2%) partial responders for an overall response rate of 4.5% among all entries. Toxic deaths were rare and reported in only 31 patients (0.5% of the entire population). Responses were usually observed in chemosensitive tumor types. Despite a low response rate reported during the first phase of cytotoxic drug development, the present analysis shows that some therapeutic benefit can be achieved.
Phase I trials response data, toxic deaths
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Abdoler, H. Taylor, and D. Wendler The Ethics of Phase 0 Oncology Trials Clin. Cancer Res., June 15, 2008; 14(12): 3692 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Italiano, C. Massard, R. Bahleda, A.-L. Vataire, E. Deutsch, N. Magne, J.-P. Pignon, G. Vassal, J.-P. Armand, and J.-C. Soria Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy Ann. Onc., April 1, 2008; 19(4): 787 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Seidenfeld, E. Horstmann, E. J. Emanuel, and C. Grady Participants in Phase 1 Oncology Research Trials: Are They Vulnerable? Arch Intern Med, January 14, 2008; 168(1): 16 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Markman "Therapeutic intent" in phase 1 oncology trials: a justifiable objective. Arch Intern Med, July 24, 2006; 166(14): 1446 - 1448. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Joffe and F. G. Miller Rethinking Risk-Benefit Assessment for Phase I Cancer Trials J. Clin. Oncol., July 1, 2006; 24(19): 2987 - 2990. [Full Text] [PDF]
|
|
|
|
|
|
D. P. Lee, J. M. Skolnik, and P. C. Adamson Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency J. Clin. Oncol., November 20, 2005; 23(33): 8431 - 8441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Horstmann, M. S. McCabe, L. Grochow, S. Yamamoto, L. Rubinstein, T. Budd, D. Shoemaker, E. J. Emanuel, and C. Grady Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002 N. Engl. J. Med., March 3, 2005; 352(9): 895 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Roberts Jr, B. H. Goulart, L. Squitieri, S. C. Stallings, E. F. Halpern, B. A. Chabner, G. S. Gazelle, S. N. Finkelstein, and J. W. Clark Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials JAMA, November 3, 2004; 292(17): 2130 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. X. Chen and I. F. Tannock Risks and Benefits of Phase 1 Clinical Trials Evaluating New Anticancer Agents: A Case for More Innovation JAMA, November 3, 2004; 292(17): 2150 - 2151. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chang Nurses' Perceptions of Phase I Clinical Trials in Pediatric Oncology: A Review of the Literature Journal of Pediatric Oncology Nursing, November 1, 2004; 21(6): 343 - 349. [Abstract] [PDF]
|
|
|
|
|
|
A. Rogatko, J. S. Babb, H. Wang, M. J. Slifker, and G. R. Hudes Patient Characteristics Compete with Dose as Predictors of Acute Treatment Toxicity in Early Phase Clinical Trials Clin. Cancer Res., July 15, 2004; 10(14): 4645 - 4651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Agrawal and E. J. Emanuel Ethics of Phase 1 Oncology Studies: Reexamining the Arguments and Data JAMA, August 27, 2003; 290(8): 1075 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Horng, E. J. Emanuel, B. Wilfond, J. Rackoff, K. Martz, and C. Grady Descriptions of Benefits and Risks in Consent Forms for Phase 1 Oncology Trials N. Engl. J. Med., December 26, 2002; 347(26): 2134 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Pentz, A. L. Flamm, J. Sugarman, M. Z. Cohen, G. Daniel Ayers, R. S. Herbst, and J. L. Abbruzzese Study of the Media's Potential Influence on Prospective Research Participants' Understanding of and Motivations for Participation in a High-Profile Phase I Trial J. Clin. Oncol., September 15, 2002; 20(18): 3785 - 3791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Lintz, R. T. Penson, B. A. Chabner, S. Mack, and T. J. Lynch Jr. A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers Oncologist, June 1, 2002; 7(90002): 8 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Cox The hopes of the dying: Examining patients' experience of participation in early phase cancer clinical trials Journal of Research in Nursing, January 1, 2002; 7(1): 60 - 73. [Abstract] [PDF]
|
|
|
|
|
|
J. D. Cheng, J. Hitt, B. Koczwara, K. A. Schulman, C. B. Burnett, D. J. Gaskin, J. H. Rowland, and N. J. Meropol Impact of Quality of Life on Patient Expectations Regarding Phase I Clinical Trials J. Clin. Oncol., January 14, 2000; 18(2): 421 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Lintz, R. T. Penson, B. A. Chabner, S. Mack, and T. J. Lynch A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers Oncologist, October 1, 1998; 3(5): 357 - 364. [Abstract] [Full Text]
|
|